A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants

Phase 1 Recruiting 48 enrolled Syneos Health Yifan Pharmaceutical (Shanghai) Co., Ltd. · collab

RandomizedCrossoverDouble-blindOther

Summary

The main aim of the study is to evaluate the pharmacokinetic (PK) biosimilarity of B-3E07 and European Union (EU) - sourced Forsteo® in healthy adult female participants.

Timeline

Start: 2026-04-10
Primary completion: 2026-09-30
Completion: 2026-10-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	B-3E07	Unknown	—	Subcutaneous
Subject	Teriparatide	Protein / enzyme biologic	—	Subcutaneous

Indications

No indication recorded.